KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Finished Goods: 2018-2024

Historic Finished Goods for Ionis Pharmaceuticals (IONS) over the last 7 years, with Dec 2024 value amounting to $276,000.

  • Ionis Pharmaceuticals' Finished Goods rose 959.00% to $2.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.1 million, marking a year-over-year increase of 959.00%. This contributed to the annual value of $276,000 for FY2024, which is 79.22% up from last year.
  • Ionis Pharmaceuticals' Finished Goods amounted to $276,000 in FY2024, which was up 79.22% from $154,000 recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Finished Goods peaked at $3.0 million during FY2020, and registered a low of $154,000 during FY2023.
  • Moreover, its 3-year median value for Finished Goods was $164,000 (2022), whereas its average is $198,000.
  • In the last 5 years, Ionis Pharmaceuticals' Finished Goods spiked by 1,064.73% in 2020 and then crashed by 87.02% in 2021.
  • Over the past 5 years, Ionis Pharmaceuticals' Finished Goods (Yearly) stood at $3.0 million in 2020, then plummeted by 87.02% to $390,000 in 2021, then crashed by 57.95% to $164,000 in 2022, then declined by 6.10% to $154,000 in 2023, then spiked by 79.22% to $276,000 in 2024.